TITUSVILLE, N.J., Nov. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA ® (lumateperone) as an adjunctive therapy ...
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson‘s Caplyta as an add-on treatment for adults with major depressive disorder. Following the FDA’s Nov. 5 decision ...
People gather next to a logo of Johnson & Johnson at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov (Reuters) -The ...
Remission (MADRS total score ≤10) was seen in 65% of patients treated with lumateperone in combination with an oral antidepressant, at 6 months. The Food and Drug Administration (FDA) has approved ...
(RTTNews) - Johnson & Johnson (JNJ) on Thursday announced that the U.S. Food and Drug Administration (FDA) has approved Caplyta as an add-on therapy with antidepressants for the treatment of major ...
One woman spent years battling symptoms she couldn’t name—until a diagnosis and treatment finally brought clarity and renewed ...
Add Yahoo as a preferred source to see more of our stories on Google. People gather next to a logo of Johnson & Johnson at the company’s booth at the 8th China International Import Expo (CIIE) in ...
(Reuters) - The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on treatment for adults with major depressive disorder, the company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results